RCT=0, PC=1, CC & NS=2
RCT=0, PC&CC=1
0=sikker ingen beh. 1= (NS) usikker kontrolgruppe
0=asia, 1=europe 2=north america, 3=africa, 4=other
Number of included patients
Mean used in calculations; both true means and estimated means
sd used for calculations
Duration of trial, years
mean follow up (years) in control group
standard deviation (years)
median follow up (years)
Lowest value in range for follow up (years)
Highest value in range for follow up (years)
total proportion of men at inclusion
number of men
Proportion of patients with cirrhosis at inclusion
Number of patients with cirrhosis
proportion of decompensated cirrhotics at inclusion (Child B&C), eg. HE, ascites
total proportion positive for HBeAg at inclusion
number HBeAg+ at follow up
=pt-hbeag, number of hbeagneg at fu
number HBsAg+ at follow up
0=no, 1=yes. UL hver 6mdr. med/uden AFP, 0.5= screnning hvert Œr
Number of hepatocellular carcinoma
Number of deaths
Mortality from HCC in control group
Number of HCC in patients with cirrhosis
number with genotype a
proportion with concurrent alcoholabuse at inclusion
number of patients with hbsag clearance
proportion with elevated alat at inclusion
proportion with HBV-DNA at inclusion
number of patients lost to follow up
Range; high-low
estimated sd^2
sd estimated from formula, for pt<16
sd estimated from range/4
sd estimated from range/6
estimated mean by (rangelow+rangehigh+2*median)/4
0=low, 1=high, 2=unknown
HCC incidence per 100 person-year
person-years, meancalc*pt